Skip to content

2025/03

Treatment of MDR Gram-negative bacilli

f3b5d87da5acf2c8d79ff55edb954115_MD5.jpeg

Green, susceptibility anticipated to be >80%; yellow, susceptibility anticipated to be 30% to 80%; red, intrinsic resistance or susceptibility anticipated to be <30%.
1, US Food and Drug Administration–approved agent; 2, synthetic tetracycline derivative; 3, imipenem-cilastatin–relebactam; 4, synthetic aminoglycoside; 5, polymyxin class.
Abbreviations: KPC, Klebsiella pneumoniae carbapenemase; NDM, New Delhi metallo-β-lactamase. (Tamma et al., 2024)

Lung ultrasound

LUS Finding Description Clinical Significance
A-lines Horizontal, repetitive lines Normal lung aeration or pneumothorax
B-lines Vertical, hyperechoic laser-like artifacts Pulmonary edema, pneumonia, ILD, ARDS
Consolidation Tissue-like hypoechoic region Pneumonia, atelectasis, infarction
Pleural Effusion Anechoic or echogenic fluid collection Heart failure, infection, malignancy
Lung Sliding Pleural shimmering movement Absent in pneumothorax or adhesions
Shred Sign Irregular lung border Pneumonia-related consolidation
Lung Point Transition between sliding and no sliding Pneumothorax